Back

A phase 2, randomized, double-blind, placebo-controlled study to assess the tolerability and pharmacodynamic effects of CRD-740, a PDE9 inhibitor, in participants with chronic heart failure

31 August 2024 (18:00 - 18:50)
Organised by: Logo
Congress Presentation Part of: Heart failure: bench to bedside Pharmacotherapy ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Professor James E Udelson

Tufts Medical Center, Inc., Boston (United States of America)

9 More presentations in this session

Presentation thumbnail
Dual pathway inhibition in patients with atherosclerosis with and without heart failure: insights from the XATOA Registry
Doctor P. Gouda (Edmonton, CA)
Abstract Slides Video
Presentation thumbnail
A newly developed small-molecule ErbB4 agonist reduces reactive cardiac fibrosis and adverse ventricular remodelling after myocardial infarction in a sex-specific manner.
Miss B. Goovaerts (Antwerp, BE)
Abstract Slides Video
Presentation thumbnail
Unmasking patients insight into SGLT2 inhibitors- a collaborative quality improvement project to enhance patient education and safety
Doctor L. Saad (Coventry, GB)
Abstract Slides Video
Presentation thumbnail
Long-acting CRF2 receptor agonist COR-1389 improves cardiopulmonary function parameters in monocrotaline-induced pulmonary hypertension and right heart failure rat model
Doctor M. Kowala (Zionsville, US)
Abstract Slides Video
Presentation thumbnail
Heart failure treatment in the last years of life - a nationwide study of 364,000 individuals
Doctor D. Lindholm (Norrtalje, SE)
Abstract Slides Video

Access the full session

Session thumbnail
Heart failure: bench to bedside

The Event

Event poster

ESC Congress 2024

31 August 2024 18:00 CET
You may be interested in
thumbnail
Congress Presentation
A phase 2, randomized, double-blind, placebo-controlled study to assess the tolerability and pharmacodynamic effects of CRD-740, a PDE9 inhibitor, in participants with chronic heart failure
thumbnail
Congress Presentation
Discussant review - CARDINAL HF
thumbnail
Congress Session
Late breaking clinical trials: medical therapy

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources